Skip to main content

Table 1 The background of the enrolled patients

From: Serum CETP status is independently associated with reduction rates in LDL-C in pitavastatin-treated diabetic patients and possible involvement of LXR in its association

Characteristics N = 53
Age (years) 61.1 ± 9.8a
Male, n (%) 27 (50.9)b
Body mass index (kg/m2) n = 52 24.8 ± 4.5
Abdominal girth (cm) n = 48 88.7 ± 9.4
Systolic blood pressure (mmHg) n = 52 127.9 ± 12.0
Diastolic blood pressure (mmHg) n = 52 73.3 ± 9.2
HbA1c (%) 7.1 ± 0.8
Complications
Type 2 diabetes, n (%) 53 (100.0)b
 diabetic neuropathy, n (%) 10 (18.9)
 diabetic nephropathy, n (%) 5 (9.4)
 diabetic retinopathy, n (%) 4 (7.5)
Hypertension, n (%) 23 (43.4)
Coronary artery disease, n (%) 4 (7.5)
Cerebral artery disease, n (%) 1 (1.9)
Peripheral artery disease, n (%) 2 (3.8)
Concurrent medications
Anti-diabetic agents  
 sulfonyl urea 28 (52.8)b
 biguanide 25 (47.2)
 α-glucosidase inhibitor 23 (43.4)
 pioglitazone 10 (18.9)
 Insulin 5 (9.4)
Anti-hypertensive agents  
 angiotensin II type 1 receptor blockers (ARBs) 18 (34.0)b
 calcium channel blockers 13 (24.5)
 diuretics 7 (13.2)
 angiotensin-converting enzyme inhibitors 5 (9.4)
Anti-lipidemic agents  
 fenofibrate 2 (3.8)b
  1. aData present mean ± SD
  2. bData present the number and its percentage (%)